BioCentury | Dec 8, 2014
Company News

Imaxio, German Cancer Research Center deal

...as a recombinant protein, which presents the antigen seven times to the immune system. Imaxio’s MVA85A-IMX313...
BioCentury | Mar 17, 2014
Company News

Emergent BioSolutions, Valneva deal

...the University of Oxford (Oxford, U.K.) formed JV OETC in 2008 to develop the university's MVA85A...
...prevent TB. Emergent said it and OETC ceased development of the vaccine last year after MVA85A...
...TB vaccines under a grant from NIH's National Institute of Allergy and Infectious Diseases (NIAID). MVA85A...
BioCentury | Sep 9, 2013
Clinical News

MVA85A-IMX313: Phase I started

...Oxford University began a single-blind, dose-escalation, U.K. Phase I trial to evaluate intradermal MVA85A-IMX313 vs. MVA85A...
...30 healthy Bacille Calmette-Guerin (BCG)-vaccinated healthy volunteers ages 18-55. Imaxio S.A. , Saint-Beauzire, France Product: MVA85A-IMX313...
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

...in futility analyses of the Phase III FLEX-M and FLEX-V trials Emergent BioSolutions Inc. (NYSE:EBS) MVA85A...
BioCentury | Feb 11, 2013
Finance

Highlights of weekly biotech stock moves

...Clinical milestones Emergent BioSolutions Inc. (NYSE:EBS) was off $0.60 to $15.70 last week after MVA85A...
...the incidence of tuberculosis infection vs. placebo in a Phase IIb trial to prevent TB. MVA85A...
BioCentury | Feb 11, 2013
Clinical News

Tuberculosis vaccine: Phase IIb data

...were vaccinated with Bacille Calmette-Guerin (BCG) at birth showed that a single intradermal dose of MVA85A...
...follow-up of 24.6 months. Specifically, there were 32 cases (2%) of TB in infants receiving MVA85A...
...Md. Aeras Global TB Vaccine Foundation , Rockville, Md. Product: Tuberculosis vaccine ( MVA85A/AERAS-485 , MVA85A...
BioCentury | Feb 5, 2013
Clinical News

Emergent's TB vaccine misses in Phase IIb trial

...Emergent BioSolutions Inc. (NYSE:EBS) said a single intradermal dose of MVA85A missed the primary efficacy endpoint...
...trial to prevent TB. Specifically, there were 32 cases (2%) of TB in infants receiving MVA85A...
...vaccines are used to vaccinate against TB infection, but they do not prevent pulmonary TB. MVA85A...
BioCentury | Apr 2, 2012
Company News

Emergent BioSolutions infectious news

...NIH's National Institute of Allergy and Infectious Diseases (NIAID) to develop tuberculosis (TB) vaccine candidate MVA85A...
...Tuberculosis Consortium Ltd., a joint venture between Emergent and the University of Oxford (Oxford, U.K.). MVA85A...
BioCentury | Mar 19, 2012
Company News

Aeras infectious news

...advanced are MVA85A and AERAS-402/Crucell Ad35 , both of which are in Phase IIb testing. MVA85A...
BioCentury | Mar 15, 2012
Company News

Gates awards $220M to Aeras for TB vaccines

...advanced are MVA85A and AERAS-402/Crucell Ad35 , both of which are in Phase IIb testing. MVA85A...
Items per page:
1 - 10 of 19